Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

'Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption'.

De Lorenzo MS, Chen W, Baljinnyam E, Carlini MJ, La Perle K, Bishop SP, Wagner TE, Rabson AB, Vatner DE, Puricelli LI, Vatner SF.

Aging Cell. 2014 Feb;13(1):102-10. doi: 10.1111/acel.12152. Epub 2013 Oct 13.

2.

Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase.

Iwatsubo K, Bravo C, Uechi M, Baljinnyam E, Nakamura T, Umemura M, Lai L, Gao S, Yan L, Zhao X, Park M, Qiu H, Okumura S, Iwatsubo M, Vatner DE, Vatner SF, Ishikawa Y.

Am J Physiol Heart Circ Physiol. 2012 Jun 15;302(12):H2622-8. doi: 10.1152/ajpheart.00190.2012. Epub 2012 Apr 13.

3.

Similarly potent inhibition of adenylyl cyclase by P-site inhibitors in hearts from wild type and AC5 knockout mice.

Braeunig JH, Schweda F, Han PL, Seifert R.

PLoS One. 2013 Jul 1;8(7):e68009. doi: 10.1371/journal.pone.0068009. Print 2013.

4.

Adenylyl cyclase type 5 in cardiac disease, metabolism, and aging.

Vatner SF, Park M, Yan L, Lee GJ, Lai L, Iwatsubo K, Ishikawa Y, Pessin J, Vatner DE.

Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H1-8. doi: 10.1152/ajpheart.00080.2013. Epub 2013 Apr 26. Review.

5.

A Food and Drug Administration-Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion.

Bravo CA, Vatner DE, Pachon R, Zhang J, Vatner SF.

J Pharmacol Exp Ther. 2016 May;357(2):331-6. doi: 10.1124/jpet.116.232538. Epub 2016 Mar 3.

PMID:
26941173
6.

Type 5 adenylyl cyclase disruption increases longevity and protects against stress.

Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H, Chen W, Hirotani S, Ishikawa Y, Sadoshima J, Vatner SF.

Cell. 2007 Jul 27;130(2):247-58.

7.

Common mechanisms for calorie restriction and adenylyl cyclase type 5 knockout models of longevity.

Yan L, Park JY, Dillinger JG, De Lorenzo MS, Yuan C, Lai L, Wang C, Ho D, Tian B, Stanley WC, Auwerx J, Vatner DE, Vatner SF.

Aging Cell. 2012 Dec;11(6):1110-20. doi: 10.1111/acel.12013. Epub 2012 Oct 17.

8.

Characterization of mouse heart adenylyl cyclase.

Göttle M, Geduhn J, König B, Gille A, Höcherl K, Seifert R.

J Pharmacol Exp Ther. 2009 Jun;329(3):1156-65. doi: 10.1124/jpet.109.150953. Epub 2009 Mar 23.

9.

Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation.

Okumura S, Kawabe J, Yatani A, Takagi G, Lee MC, Hong C, Liu J, Takagi I, Sadoshima J, Vatner DE, Vatner SF, Ishikawa Y.

Circ Res. 2003 Aug 22;93(4):364-71. Epub 2003 Jul 17.

10.

Inhibition of adenylyl cyclase type 5 increases longevity and healthful aging through oxidative stress protection.

Vatner SF, Pachon RE, Vatner DE.

Oxid Med Cell Longev. 2015;2015:250310. doi: 10.1155/2015/250310. Epub 2015 Apr 7. Review.

11.

Type 5 adenylyl cyclase disruption leads to enhanced exercise performance.

Vatner DE, Yan L, Lai L, Yuan C, Mouchiroud L, Pachon RE, Zhang J, Dillinger JG, Houtkooper RH, Auwerx J, Vatner SF.

Aging Cell. 2015 Dec;14(6):1075-84. doi: 10.1111/acel.12401. Epub 2015 Oct 1.

12.

Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect.

Mann L, Heldman E, Bersudsky Y, Vatner SF, Ishikawa Y, Almog O, Belmaker RH, Agam G.

Bipolar Disord. 2009 Dec;11(8):885-96. doi: 10.1111/j.1399-5618.2009.00762.x.

PMID:
19922557
13.

Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress.

Okumura S, Vatner DE, Kurotani R, Bai Y, Gao S, Yuan Z, Iwatsubo K, Ulucan C, Kawabe J, Ghosh K, Vatner SF, Ishikawa Y.

Circulation. 2007 Oct 16;116(16):1776-83. Epub 2007 Sep 24.

14.

Adenylyl cyclase type 5 contributes to corticostriatal plasticity and striatum-dependent learning.

Kheirbek MA, Britt JP, Beeler JA, Ishikawa Y, McGehee DS, Zhuang X.

J Neurosci. 2009 Sep 30;29(39):12115-24. doi: 10.1523/JNEUROSCI.3343-09.2009.

15.

Adenylyl cyclase type 5 protein expression during cardiac development and stress.

Hu CL, Chandra R, Ge H, Pain J, Yan L, Babu G, Depre C, Iwatsubo K, Ishikawa Y, Sadoshima J, Vatner SF, Vatner DE.

Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1776-82. doi: 10.1152/ajpheart.00050.2009. Epub 2009 Sep 4.

16.

Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease.

Park HY, Kang YM, Kang Y, Park TS, Ryu YK, Hwang JH, Kim YH, Chung BH, Nam KH, Kim MR, Lee CH, Han PL, Kim KS.

J Neurosci. 2014 Aug 27;34(35):11744-53. doi: 10.1523/JNEUROSCI.0864-14.2014.

17.

Functional adenylyl cyclase inhibition in murine cardiomyocytes by 2'(3')-O-(N-methylanthraniloyl)-guanosine 5'-[gamma-thio]triphosphate.

Rottlaender D, Matthes J, Vatner SF, Seifert R, Herzig S.

J Pharmacol Exp Ther. 2007 May;321(2):608-15. Epub 2007 Feb 6.

18.

Adenylyl cyclase type 5 disruption prolongs longevity and protects the heart against stress.

Vatner SF, Yan L, Ishikawa Y, Vatner DE, Sadoshima J.

Circ J. 2009 Feb;73(2):195-200. Epub 2008 Dec 24. Review.

19.

Type 5 adenylyl cyclase plays a major role in stabilizing heart rate in response to microgravity induced by parabolic flight.

Okumura S, Tsunematsu T, Bai Y, Jiao Q, Ono S, Suzuki S, Kurotani R, Sato M, Minamisawa S, Umemura S, Ishikawa Y.

J Appl Physiol (1985). 2008 Jul;105(1):173-9. doi: 10.1152/japplphysiol.01166.2007. Epub 2008 May 1.

20.

Vidarabine is neither a potent nor a selective AC5 inhibitor.

Seifert R.

Biochem Pharmacol. 2014 Feb 15;87(4):543-6. doi: 10.1016/j.bcp.2013.12.025. Epub 2014 Jan 4. Review.

PMID:
24398424
Items per page

Supplemental Content

Write to the Help Desk